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Abstract: Diet and lifestyle changes have led to worldwide increases in the prevalences of 
obesity and metabolic syndrome, resulting in substantially greater incidence of nonalcoholic fatty 
liver disease (NAFLD). NAFLD is considered a hepatic manifestation of metabolic syndrome 
and is related to diabetes, insulin resistance, central obesity, hyperlipidemia, and hypertension. 
Nonalcoholic steatohepatitis (NASH) is an entity that describes liver inflammation due to 
NAFLD. Growing evidence suggests that NAFLD is a multisystem disease with a clinical burden 
that is not only confined to liver-related morbidity and mortality, but that also affects several 
extra-hepatic organs and regulatory pathways. Thus, NAFLD is considered an important public 
health issue, but there is currently no effective therapy for all NAFLD patients in the general 
population. Studies seeking optimal therapy for NAFLD and NASH have not yet led to develop-
ment of a universal protocol for treating this growing problem. Several pharmacological agents 
have been studied in an effort to improve insulin resistance and the proinflammatory mediators 
that may be responsible for NASH progression. Cardiovascular risk factors are highly prevalent 
among NASH patients, and the backbone of treatment regimens for these patients still com-
prises general lifestyle interventions, including dietary changes and increased physical activity. 
Vitamin E and thiazolidinedione derivatives are currently the most evidence-based therapeutic 
options, but only limited clinical evidence is available regarding their long-term efficacy and 
safety. Vitamin D and renin–angiotensin–aldosterone system blockers are promising drugs that 
are currently being intensively investigated for use in NAFLD/NASH patients.
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Introduction
Nonalcoholic fatty liver disease (NAFLD) is now the most common cause of chronic 
liver disease, which is predicted to be the most frequent indication for liver trans-
plantation by 2030.1 Diet and lifestyle changes have led to worldwide increases in 
the prevalence of obesity and metabolic syndrome (MS), resulting in a substantially 
higher NAFLD incidence. NAFLD is defined as lipid-deposit accumulation in the 
hepatocytes, which is not due to excessive alcohol use. This disease is related to 
type 2 diabetes mellitus, insulin resistance (IR), central obesity, hyperlipidemia, and 
hypertension, and is considered a hepatic manifestation of MS. NAFLD encompasses 
a spectrum of diseases ranging from simple steatosis to nonalcoholic steatohepatitis 
(NASH), which in its most severe form can lead to liver fibrosis, cirrhosis, and hepa-
tocellular carcinoma.1,2
NASH – an entity describing liver inflammation due to NAFLD – represents 
the most severe histologic form of NAFLD, defined by fat accumulation in the 
liver exceeding 5% of its weight.3 NAFLD does not always lead to inflammation. 
Patients who develop NASH can remain asymptomatic for years, but carry a seri-
ous risk of liver fibrosis/cirrhosis and hepatocellular carcinoma, and therefore of 
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chronic liver failure. Although the pathogenesis of NAFLD 
development and progression towards NASH is somewhat 
unclear, IR is reportedly related to obesity and plays a central 
role in NAFLD pathogenesis. According to the literature, 
imbalances between pro- and antioxidant mechanisms and 
between pro- and anti-inflammatory cytokines are important 
components of NAFLD pathogenesis and disease progres-
sion toward NASH and fibrosis. Among the central inflam-
matory signaling pathways that drive the transition from 
chronic liver injury to fibrosis and hepatocarcinoma, it is 
thought that oxidative stress is involved in NAFLD onset 
and progression.3–5
There exists growing evidence that NAFLD is a multi-
system disease, with clinical consequences extending beyond 
those associated with liver-related morbidity and mortality, 
and affecting several extra-hepatic organs. Recent findings 
suggest that NAFLD increases the risks of type 2 diabetes 
mellitus, cardiovascular diseases (CVDs), and chronic kidney 
disease (CKD). Over the last decade, increasing attention 
has been focused on NAFLD-related CKD.1 Musso et al6 
recently conducted a meta-analysis including 33 studies 
(63,902 participants), which revealed an association between 
NAFLD and increased CKD prevalence and incidence. 
Among patients with biopsy-proven NAFLD, NASH was 
associated with higher CKD prevalence and incidence 
compared to simple steatosis, and more advanced fibrosis 
was associated with higher CKD prevalence and incidence 
than lower fibrosis stages. Moreover, NAFLD severity was 
positively associated with CKD severity. Evidence also links 
NAFLD to other chronic diseases, including sleep apnea, 
colorectal cancers, osteoporosis, psoriasis, and various 
endocrinopathies.1
The clinical implication of these findings is that patients 
with NAFLD may benefit from more intensive surveillance 
and early treatment interventions to decrease their risks of 
CVD and kidney complications, as well as other diseases, 
such as colorectal cancer.1 Thus, NAFLD is increasingly 
considered an important public health issue. There is cur-
rently no therapy that is effective for all NAFLD patients in 
the general population. Studies aiming to identify optimal 
therapies for NAFLD and NASH have not yet developed 
a universal protocol that successfully treats this growing 
problem.
NAFLD is often associated with MS components and 
IR, and these underlying conditions play crucial roles in 
its pathogenesis.7 The most important factors in NAFLD 
pathogenesis are free fatty acids (FFA), tumor necrosis fac-
tor (TNF)-alpha, and adiponectin, which promote NAFLD 
by modulating the hepatic inflammatory response. Insulin 
allows FFA esterification and triglyceride fat storage in 
adipose tissue. Development of IR leads to inappropriate 
shifting of FFA to nonadipose tissue, such as the liver. 
IR increases the influx of FFA to the liver via decreased 
inhibition of lipolysis as well as increased de novo intrahe-
patic FFA synthesis (de novo lipogenesis). TNF-alpha is a 
proapoptotic cytokine that plays major roles in recruiting 
inflammatory cells to injured tissues and in promoting IR. 
NAFLD patients also show decreased levels of “protective 
adipokines”, such as adiponectin, likely as a consequence of 
IR. Decreased adiponectin levels lead to fatty acid oxidation 
and increased fat accumulation in the liver. Increased hepatic 
FFA activate signals that increase TNF-alpha production in 
hepatocytes, which consequently inhibits hepatic adiponectin 
activity, promoting NAFLD and hepatic IR.8,9
Liver steatosis does not always result in hepatocellular 
injury, suggesting that additional insults are necessary. 
Five years ago, Tilg and Moschen10 proposed the “parallel 
hit hypothesis” in which many hits derived from the gut 
and visceral adipose tissue may act in parallel to produce 
hepatic inflammation, consequently leading to steatohepa-
titis. Moreover, IR is a common feature among NAFLD/
NASH patients and plays a central role in the complex 
interaction of genetic and environmental factors that con-
tribute to NAFLD pathogenesis. Thus, improving insulin 
sensitivity would be expected to reduce NAFLD/NASH 
progression.7
Additionally, the gut–liver axis has attracted much 
interest particularly regarding the pathogenesis of NAFLD 
because gut microbiota contribute to nutritional absorption 
and storage. The exact mechanisms by which gut microbiota 
contribute to NAFLD are poorly understood, although the 
role of gut microbiota in the development of NAFLD has 
been well documented in recent years. Thus, normaliza-
tion of gut microbiota using probiotics or prebiotics is a 
promising treatment option for NAFLD and requires further 
investigations.11,12
It is likely that NAFLD/NASH management will require 
the treatment of not only liver disease itself but also of these 
associated metabolic abnormalities, as well as prevention of 
the “hits”.
The present paper will discuss the full spectrum of 
investigated therapeutic options for NASH. Approaches 
to NAFLD/NASH treatment can generally be divided into 
lifestyle changes, pharmacological interventions, surgical 
interventions (bariatric surgery), and other interventions 
(phlebotomy).13
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Lifestyle changes
Among NASH patients, cardiovascular risk factors are highly 
prevalent and the backbone of treatment options comprises 
general lifestyle interventions, including dietary changes 
and increased physical activity.14 Evidence suggests that a 
5%–10% reduction of baseline body weight improves IR, 
aminotransferases levels, and histological findings. Thus, 
there are empirically based dietary recommendations that 
patients with NAFLD and NASH eat a hypoenergetic diet 
to promote weight loss.7,14 In a randomized controlled 
trial, Promrat et al15 confirm that modest weight reduction 
(7%–10%) achieved through lifestyle intervention leads to 
improved liver histology in NASH patients. These find-
ings support the effectiveness of body-weight reduction for 
patients with obesity-related NASH.
There is not yet sufficient evidence indicating what spe-
cific diet should be followed to achieve the best outcome. 
It is assumed that diets rich in whole grains tend to promote 
weight reduction, reduce liver fat, and protect against inflam-
mation leading to NASH; however, this is not verified by 
clinically based evidence.16 Compared to current dietary 
advice, a Mediterranean diet appears to be a better option 
for NAFLD/NASH management. The Mediterranean diet 
is a pyramid characterized with the abundance of vegetable 
foods and cereals, such as green and yellow vegetables, 
salads, legumes, bread, pasta, fruits and nuts. Olive oil is 
the main source of fat and the intake of fish, poultry, dairy 
products, and eggs is moderate. In addition, different amounts 
of wine are usually consumed in moderation with meals. 
Animal fats used in butter, cream, and lard are not included 
in this diet.17 One study in an insulin-resistant population 
with NAFLD showed that even without weight loss, the 
Mediterranean diet reduces liver steatosis and improves 
insulin sensitivity.18 Moreover, in recent systematic reviews 
and meta-analyses, adhering to or adopting a Mediterranean 
dietary regimen presents a beneficial effect on the prevention 
and the resolution of MS, as well as on individual metabolic 
parameters.17,19 Additionally, reducing dietary fructose may 
be beneficial. Daily fructose ingestion is associated with 
reduced hepatic steatosis but increased fibrosis, and in older 
adults it is associated with hepatic inflammation and hepa-
tocyte ballooning.20,21 In a pediatric population, increased 
hepatocyte ballooning was seen in patients with reduced 
vitamin C consumption, while patients with definite NASH 
showed significantly higher fructose intake.22
Askari et al23 demonstrated that daily cinnamon intake 
may effectively improve NAFLD characteristics. As NASH 
is strongly associated with MS components and CVD risk, 
omega-3 fatty acids could be useful in MS-related conditions 
and can probably reduce the CVD risk in NASH patients.24 
Malaguarnera et al25 demonstrated that some probiotics have 
beneficial effects as a complementary therapeutic approach 
in NAFLD patients. Their results showed that, compared to 
lifestyle modification alone, Bifidobacterium longum along 
with fructose oligosaccharides and lifestyle modification led 
to significantly greater reductions in steatosis and NASH 
activity index.25,26 Interestingly, the metabolic effects of 
coffee consumption have also attracted great interest among 
hepatology researchers. Some preliminary data suggest that 
coffee consumption is associated with NASH improvement. 
However, the exact mechanism of these beneficial effects is 
not yet understood and further investigation is needed.27
Exercise is another useful lifestyle-related intervention 
for NAFLD/NASH patients. Among patients with obesity-
related NAFLD, aerobic exercise sessions of 30–60 minutes 
performed three to four times weekly for 4–12 weeks are 
shown to improve fatty liver changes, even without accompa-
nying body-weight reduction. However, studies investigating 
the usefulness of exercises in NAFLD patients have not used 
histological liver changes as an end point.7
In summary, current evidence suggests that a community-
based lifestyle-modification program including dietary 
changes and exercise targeting significant weight loss is effec-
tive in reducing liver fat in NAFLD/NASH patients.28,29
Pharmacological interventions
Pharmacological interventions for NAFLD/NASH patients 
are targeted to treat underlying MS components (eg, obesity, 
diabetes, hypertension, and dyslipidemia) as well as liver 
dysfunction itself.7 Many clinical studies have investigated 
numerous drugs and supplements, but researchers have not 
yet identified a completely safe and effective therapy that 
can be recommended for NASH treatment. Individuals with 
NAFLD/NASH show heterogeneity of pathogenic pathways, 
necessitating individualized treatment according to the 
underlying pathogenesis.27
insulin sensitizers
IR is a major mechanism in NAFLD development and 
progression; thus, research has focused on the potential 
therapeutic effect of insulin sensitizers on NAFLD/NASH. 
In particular, metformin and thiazolidinediones (TZDs) have 
been intensively investigated in terms of improving IR in 
NAFLD/NASH patients. The insulin sensitizer metformin 
is a biguanide medication that is commonly used to treat 
type 2 diabetes mellitus. Metformin improves IR through 





the reduction of hepatic gluconeogenesis, lipogenesis, and 
fatty acid oxidation; increasing peripheral and hepatic insulin 
sensitivity; decreasing intestinal glucose absorption; and 
lowering serum lipid concentration. Early pilot studies of 
metformin in NAFLD/NASH patients showed promising 
results in terms of improving fatty liver disease and aminot-
ransferase levels, as well as reversing hepatomegaly and 
steatosis.9 However, in the largest randomized controlled 
trial, metformin failed as a treatment option compared to the 
placebo among NAFLD/NASH patients.30 Thus, metformin 
is not recommended as a therapy for NASH.
TZDs are insulin sensitizers that increase insulin- 
dependent glucose disposal and reduce hepatic glucose out-
put by binding to peroxisome proliferator-activated receptor 
(PPAR)-γ. In one large study, pioglitazone induced acute 
improvement of adipose tissue IR that was associated with 
changes in liver histology, including fibrosis.31 Pioglitazone 
treatment is also associated with increased plasma levels of 
adiponectin, an adipokine that is often decreased in NASH 
patients.32 On the other hand, pioglitazone use is also associ-
ated with some side effects, including weight gain, edema, 
heart failure, and bone density reduction. Additionally, pio-
glitazone use for more than 2 years carries an increased risk 
of bladder cancer.33 In the United States, the Food and Drug 
Administration currently recommends avoidance of pioglita-
zone in cases of active bladder cancer, and caution regarding 
its use in patients with history of bladder cancer.9
Another TZD medication is rosiglitazone, which is widely 
used to treat patients with type 2 diabetes mellitus. Its safety 
in terms of CVD morbidity and mortality has been questioned. 
Rosiglitazone use is prohibited in Europe according to the 
recommendations of the Europe Medicines Agency, and 
its use is highly restricted in the USA.9 However, the latest 
data show that rosiglitazone use is not associated with sig-
nificantly increased risk of myocardial infarction or of death 
from cardiovascular causes.34 Rosiglitazone treatment has a 
substantial antisteatogenic effect in the first year of treatment, 
but no additional benefit with longer therapy despite its main-
tained effect on insulin sensitivity and transaminase levels. 
This suggests that improving insulin sensitivity may not be 
sufficient for NASH therapy.35 It has also been noted that 
TZD therapy in the absence of lifestyle modifications is not 
effective.36 Some studies report that NASH often recurs after 
discontinuation of TZD therapy,37 suggesting the need for 
long-term therapy; however, long-term therapy is problematic 
due to the above-mentioned side effects of TZD use.
One attractive potential treatment involves the combination 
of TZDs with other medications that improve their efficacy 
or ameliorate their weight-gain side effects. In one study, 
137 subjects with biopsy-proven NASH received 4 mg rosigli-
tazone twice-daily; 4 mg rosiglitazone and 500 mg metformin 
twice-daily; or 4 mg rosiglitazone twice-daily and 50 mg losartan 
once-daily for 48 weeks. The primary outcome revealed that the 
treatment groups did not significantly differ in the investigated 
histologic parameters, indicating no greater benefit of the drug 
combinations compared to rosiglitazone alone.38 On the other 
hand, a recently published evidence-based clinical practice 
review article by an expert panel from the Chilean Gastroen-
terological Society and the Chilean Hepatology Association 
suggests that the combination of pioglitazone with vitamin E is 
a good pharmacological choice for patients with biopsy-proven 
NASH, although evidence regarding the long-term safety and 
efficacy of this treatment is insufficient.39
Antioxidants
Many antioxidants are reported to show potential beneficial 
liver effects. Oxidative stress and depletion of endogenous 
antioxidants are key mechanisms responsible for liver dam-
age and disease progression in NAFLD/NASH patients. One 
antioxidant that has been well-studied for NASH treatment is 
vitamin E (α-tocopherol), which is a fat-soluble free radical 
scavenger as well as a chain-breaking antioxidant in free 
radical reactions, such as lipid peroxidation. It is proposed 
that vitamin E acts on PPARs, apoptosis-regulating genes, 
and transforming growth factor beta 1, which is believed to 
promote fibrosis.9,27
Data suggest that vitamin E is associated with decreasing 
aminotransferase levels and with improved liver histology 
in NASH patients.31,40 A large randomized controlled trial 
of adult NASH patients with and without diabetes found 
that, compared to placebo, daily oral vitamin E admin-
istration (800 IU/d) for 96 weeks significantly improved 
serum aminotransferase levels, hepatic steatosis, and lobu-
lar inflammation compared, but not the extent of hepatic 
fibrosis.41 More recently, the TONIC trial showed significant 
histological improvements in children with biopsy-proven 
NASH who took vitamin E.30 Another randomized controlled 
trial reported that 6 months of administration of vitamin E 
(1,000 IU/d) and vitamin C (1,000 mg/d) resulted in signifi-
cant improvement in hepatic fibrosis among patients with 
NASH.42 Based on the current literature, vitamin E treatment 
appears to be a good option for improving histology and 
aminotransferase activity among NASH patients. American 
guidelines for NAFLD management recommend the use of 
vitamin E as a first-line pharmacotherapy for nondiabetic 
patients with biopsy-proven NASH.
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However, it must be noted that serious concerns have 
been raised regarding the safety of long-term vitamin E 
treatment. Thus, physicians who chose to initiate vitamin E 
therapy should consider the potential risk of long-term 
treatment with this drug. In particular, vitamin E is not rec-
ommended in NASH patients with diabetes and high CVD 
risk. Treatment with vitamin E is also not recommended 
in NAFLD patients without liver biopsy, NASH cirrhosis, 
or cryptogenic cirrhosis.11,27,43 Actually, according to the 
American guidelines for the treatment of NAFLD, vitamin E 
is not recommended to treat NASH in diabetic patients, 
NAFLD without liver biopsy, NASH cirrhosis, or crypto-
genic cirrhosis.13,44
There remains a need for further investigations with 
longer follow-up periods to examine vitamin E safety and 
efficacy, particularly with regard to important end points, 
such as prevention of cirrhosis and long-term survival in 
NASH patients. Future studies should also determine how 
long NASH patients should continue vitamin E therapy, 
and how different vitamin E formulations and sources may 
alter efficacy.
Ursodeoxycholic acid
Ursodeoxycholic acid (UDCA) is a hydrophilic bile acid 
with anti-inflammatory, antiapoptotic, and immunomodu-
latory properties that may make it useful for NASH treat-
ment. Uncontrolled clinical studies show that UDCA has 
beneficial effects on NASH, but these results were not 
confirmed in a large controlled trial using UDCA. A pilot 
study conducted by Laurin et al45 shows that NASH treat-
ment with UDCA for 12 months significantly improved 
alkaline phosphatase, ALT, and hepatic steatosis. Addi-
tionally, a randomized, double-blind, placebo-controlled 
multicenter trial was initiated to evaluate the efficacy 
and safety of high-dose UDCA (28–35 mg/kg per day) in 
126 patients with biopsy-proven NASH and elevated ALT 
levels. In this analysis, high-dose UDCA significantly 
improved aminotransferase levels, serum fibrosis markers, 
and selected metabolic parameters (markers of glycemic 
control and IR).46
On the other hand, a randomized, placebo-controlled study 
testing high-dose UDCA (23–28 mg/kg/day) did not show 
beneficial effects of UDCA in NASH treatment. Compared 
to placebo, this high-dose UDCA treatment failed to improve 
the overall histology in NASH patients.47 Overall, current 
data show no substantial benefit of UDCA in NASH treat-
ment, and American guidelines do not recommend UDCA 
for the treatment of NAFLD/NASH. Additional studies of 
UDCA treatment with histologic end points are warranted 
in this patient group.13
Obeticholic acid
Obeticholic acid is a synthetic bile acid that acts as a potent 
activator of the farnesoid X nuclear receptor, and that reduces 
liver fat and fibrosis in animal models of fatty liver disease. 
A recent multicenter, double-blind, placebo-controlled, par-
allel group, randomized clinical trial at US medical centers 
recently assessed efficacy of obeticholic acid in patients 
with non-cirrhotic NASH. The patients were randomly 
assigned 1:1 to receive orally administered treatment with 
obeticholic acid (25 mg daily) or placebo for 72 weeks. 
After a follow-up period, obeticholic acid was associated 
with improved histological features of NASH compared to 
placebo.48 Further studies of this drug’s long-term benefits 
and safety are needed.
Bicyclol
Bicyclol is a synthetic compound that protects the liver against 
oxidation and lipid injuries, and that is widely used to treat 
chronic hepatitis B and C viral infections in the People’s 
Republic of China.49 Han et al50 recently investigated the effi-
cacy of bicyclol among 248 enrolled patients with NAFLD and 
impaired glucose metabolism. After lifestyle changes and met-
formin treatment (500 mg orally three times daily), the patients 
were equally randomized to two 24-week treatment groups: 
bicyclol 25 mg three times daily or vitamin E (α-tocopherol) 
100 mg three times daily (control). Liver histological assess-
ments revealed that both groups showed decreased steatosis, 
inflammation, hepatocellular ballooning, and NAFLD activ-
ity scores (NAS) after treatment (P,0.01). However, the 
decreases in inflammation and NAFLD activity scores were 
statistically greater in the bicyclol group compared to the 
vitamin E group (P,0.01). Further randomized controlled 
studies are needed to assess the efficacy and safety of bicyclol 
as a treatment option for NAFLD/NASH patients.
Lipid-lowering drugs
NAFLD/NASH is strongly associated with obesity, dyslipi-
demia, and CVD risk. Two types of lipid-lowering drugs have 
been assessed for NASH treatment: 1) HMG-CoA reductase 
inhibitors (statins) that inhibit hepatic cholesterol synthe-
sis; and 2) the Niemann-Pick C1-Like protein antagonist 
ezetimibe, which is a key player in cholesterol absorption 
from the small intestine. As these medications also have pos-
sible anti-inflammatory effects, lipid-lowering agents were 
investigated in patients with NAFLD/NASH.7 Nelson et al51 





assessed the utility of simvastatin therapy in patients with 
biopsy-proven NASH and hyperlipidemia. Compared with 
placebo, the simvastatin group showed a 26% reduction in 
low-density lipoprotein, but there were no statistically signifi-
cant improvements in serum aminotransferase levels, hepatic 
steatosis, necroinflammatory activity, or stage of fibrosis. 
More recently, a small study investigated the efficacy of rosu-
vastatin therapy (10 mg/day) for 1 year in patients with MS, 
NASH on liver biopsy, and dyslipidemia (but without 
diabetes or arterial hypertension). Their preliminary findings 
suggest that rosuvastatin could ameliorate NASH within a 
year of treatment in patients with dyslipidemia.52 Finally, a 
recent randomized study by Takeshita et al53 reported that 
ezetimibe administration (10 mg/day for 6 months) was 
associated with improvement in hepatic fibrosis; however, 
ezetimibe therapy also led to increased hepatic long-chain 
fatty acids and HbA1c among NAFLD patients. However, 
a recent study on the use of ezetimibe in NASH reported 
that the use of ezetimibe did not significantly reduce liver 
fat in NASH.54
Statins decrease lipid levels both peripherally and viscer-
ally, specifically in the liver. Consequently, aminotransferase 
levels may transiently increase when fat is removed from 
the liver. However, this transient elevation of liver enzymes 
does not progress to liver injury; therefore, it is not necessary 
to stop statin treatment if aminotransferase levels increase 
shortly after statin administration.9
Statins can improve the adverse outcomes of conditions 
commonly associated with NASH (such as hyperlipidemia, 
diabetes mellitus, and MS), potentially justifying their use 
in patients with NASH.55 While statin administration may 
help to improve metabolic status and reduce CVD risk in 
NAFLD/NASH patients, its use in NASH treatment has not 
been approved due to the lack of randomized controlled trials 
including histological evidence.9,56 Thus, there remains a need 
for investigations with larger sample sizes and histological 
evidence in NASH patients.
Renin–angiotensin system blockers
Angiotensin-converting enzyme inhibitors and angiotensin 
receptor blockers are attractive options for hypertension 
treatment. Substantial data show that these drugs are use-
ful in slowing fibrosis progression in diabetic nephropathy 
and heart failure. The function of the renin–angiotensin–
aldosterone system (RAAS) in NAFLD has been the subject 
of considerable interest in recent years due to observations 
that this system may regulate fibrosis and tissue repair, and 
is thus a target for treatment with RAAS blockers. Current 
data suggest that the RAAS may be important in NAFLD 
pathogenesis, with angiotensin II (Ang II) playing a critical 
role in liver inflammation and fibrosis development. Thus, 
angiotensin-converting enzyme inhibitors and angiotensin 
receptor blockers could be a useful therapeutic option for 
NAFLD patients.57–61
The RAAS is classically conceived as a hormonal cas-
cade responsible for controlling cardiovascular, renal, and 
adrenal functions, which regulates hydroelectrolytic balance 
and blood pressure through Ang II actions. However, recent 
data show that interaction against RAAS both reduces blood 
pressure and improves insulin sensitivity. RAAS suppression 
improves intracellular insulin signaling through activation 
of PPAR-γ, leading to improved control of adipose tissue 
proliferation and adipokine production. Moreover, RAAS 
suppression is associated with prevention of hepatic stel-
late cell activation and, consequently, prevention of hepatic 
inflammation and fibrogenesis. Additionally, local suppres-
sion of RAAS in the liver slows down the vicious cycle 
linking steatosis to necroinflammation, and prevents fibrosis. 
On the other hand, modulating the pancreatic effects of Ang 
II makes it possible to reach adequate insulin secretion and 
better metabolic balance.57–62 As mentioned earlier, IR is rec-
ognized as the pathophysiological hallmark of NAFLD.1
Several studies have investigated the efficacy of RAAS 
blockers, showing their beneficial effect in NAFLD 
patients.60,63–66 Considering the standard and wide use of 
RAAS blockers in the treatment of hypertension, a compo-
nent of MS, further well-designed randomized controlled 
trials of RAAS blockers in NAFLD patients should be 
encouraged.
vitamin D
Vitamin D has long been considered to mainly function only 
in bone metabolism. However, this vitamin has recently been 
recognized as a hormone with immunomodulatory, anti-
inflammatory, and antifibrotic properties.67,68 Vitamin D defi-
ciency is defined as a serum 25-hydroxyvitamin D (25(OH)D) 
level of ,50 nmol/L (,20 ng/mL), while serum 25(OH)D 
levels of 50–75 mmol/L (20–30 ng/mL) are considered 
vitamin D insufficiency.69 Many authors hypothesize that low 
vitamin D levels are strongly associated with components of 
MS, and it has been reported that serum 25(OH)D levels are 
inversely related to body mass index (BMI), body fat content, 
hypertension, IR, and diabetes.69,70
The liver is a central organ in vitamin D synthesis, where 
25(OH)D occurs and where the majority of vitamin D- 
binding protein is synthesized. Recently, it was recognized 
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that vitamin D deficiency is frequently present in chronic 
liver disease,68 and an association between vitamin D levels 
and NAFLD has been observed in both adults and children. 
Targher et al71 reported that 25(OH)D levels were inversely 
correlated with histological features of biopsy-proven 
NAFLD/NASH. These findings have been confirmed by other 
authors.70,72–74 Moreover, vitamin D exerts antiproliferative 
and antifibrotic effects on fibrosis progression in NAFLD. 
This process is mediated by the antagonistic actions of 
VDRs on the SMAD transcription factor. VDRs are widely 
expressed in hepatic stellate cells, which are responsible for 
the excessive extracellular matrix deposition that leads to the 
destruction of normal liver architecture.75
The above observations regarding the link between 
vitamin D serum levels, NAFLD risk factors, and NAFLD 
severity suggest that vitamin D supplementation might 
represent a new therapeutic option in NASH management. 
Further well-designed studies are needed to investigate this 
possibility.
Silybum marianum, or milk thistle
During the last years, there has been considerable interest in 
the potential efficacy of silymarin and silybin, two natural 
products derived from the milk thistle (MT) plant Silybum 
marianum. Silybum marianum, or MT, is a well-researched 
plant in the treatment of various liver diseases. The active 
complex of MT is a lipophilic extract from the seeds of 
the plant and is composed of three isomer flavonolignans 
(silybin, silydianin, and silychristin) collectively known as 
silymarin. Silymarin acts as an antioxidant by reducing free 
radical production and lipid peroxidation, and has antifibrotic 
activity.76,77 In the study by Loguercio et al78 treatment with 
Realsil that comprises the silybin–phytosome complex 
(silybin plus phosphatidylcholine [PPC]) coformulated with 
vitamin E for 12 months was associated with improvement 
in liver enzymes, IR, and liver histology, without increases 
in body weight.
PPC
PPC is the main component of lecithin. PPC is an integral 
part of cell membranes, essential for their structural and 
functional integrity. Cell membranes act like gatekeepers, 
allowing nutrients into the cells but blocking damaging toxins 
from gaining entrance. PPC has been shown to enhance cell 
membrane function throughout the body. Horejsová et al79 in 
their study have shown that taking the supplement every day 
(along with low doses of fatty acids, B vitamins, and vitamin 
E) reduced fatty liver symptoms within 6 months in more than 
half of the study participants. In another study by Li et al80 
PPC increased the breakdown of collagen, the connective-
tissue protein that tends to accumulate in liver disease, 
promoting the scarring behind fibrosis and cirrhosis.
Bariatric surgery
Obesity and IR represent the main pathological path towards 
NAFLD and NASH, and thus weight loss is a first-line rec-
ommendation to individuals with NAFLD. Bariatric surgery 
leads to long-term weight loss and improvement in obesity-
related disorders. Caiazzo et al81 performed a prospective 
longitudinal study that followed 1,236 obese patients for 
up to 5 years after Roux-en-Y gastric bypass or adjustable 
gastric banding to investigate the efficacy of these surgical 
methods for treatment of obesity-related NAFLD. Liver 
biopsy samples were available for 1,201 patients at baseline, 
578 patients at 1 year, and 413 patients at 5 years. Their 
analysis revealed that all NAFLD parameters improved after 
surgery, with significantly greater improvement after Roux-
en-Y gastric bypass than after adjustable gastric banding.
The current evidence suggests that bariatric surgery in 
NAFLD/NASH patients will decrease the grade of steatosis, 
hepatic inflammation, and fibrosis. However, NAFLD per 
se is not an indication for bariatric surgery. Further inves-
tigations are needed to determine the beneficial effects of 
bariatric surgery in NAFLD patients who are at high risk 
of developing liver cirrhosis. There is also a need for more 
data regarding the role of bariatric surgery in modulation 
of NAFLD-related complications, such as CVD, diabetes, 
and hepatocellular carcinoma, as well as information about 
performing bariatric surgery before liver transplantation in 
cases of NASH-related liver cirrhosis.82–84
Phlebotomy
Patients with NAFLD and MS often show increased hepatic 
iron deposition and elevated serum ferritin levels. Available 
data indicate that 20%–30% of patients with NAFLD show 
hyperferritinemia with mild hepatic iron accumulation, which 
is commonly referred to as dysmetabolic iron overload syn-
drome. Besides directly inducing liver damage, excess iron 
is involved in MS pathogenesis by inducing adipose tissue 
IR and modifying adipokine release. Hyperferritinemia and 
increased iron stores have also been associated with hepato-
cellular carcinoma in patients with NAFLD.85,86
Valenti et al85 investigated phlebotomy efficacy in 38 
NAFLD patients who were randomized to phlebotomy 
(n=21) or lifestyle changes alone (n=17). Phlebotomy was 
performed by removing 350 mL of blood every 10–15 days, 





and this procedure led to no adverse events. The main study 
outcome was improvement of liver damage in 2 years accord-
ing to NAFLD activity score. The secondary outcome was 
improvement in liver enzymes, including ALT, aspartate ami-
notransferase, and gamma-glutamyltransferase. Phlebotomy 
was associated with normalization of iron parameters and 
amelioration of liver enzymes. Compared to lifestyle changes 
alone, iron depletion by phlebotomy was associated with a 
higher rate of improvement of histological liver damage in 
patients with NAFLD and hyperferritinemia.
A more recent prospective 6-month randomized con-
trolled trial examined the impact of phlebotomy on the 
background of lifestyle advice in NAFLD patients. Primary 
end points were hepatic steatosis (quantified by magnetic 
resonance imaging) and liver injury (determined by ala-
nine aminotransaminase and cytokeratin-18). Secondary 
end points included IR measured by the insulin sensitivity 
index and homeostasis model of assessment, and systemic 
lipid peroxidation determined by plasma F2-isoprostane 
levels. In contrast to earlier findings, the results of this 
study showed that ferritin reduction by phlebotomy did not 
improve liver enzymes, hepatic fat, or IR among subjects with 
NAFLD.87 To resolve this controversy, larger trials should 
be conducted to evaluate phlebotomy treatment in patients 
with severe NAFLD/NASH and hyperferritinemia resistant 
to lifestyle changes.
Algorithm for practicing physicians  
on the management of NAFLD/ 
NASH patients
NAFLD and NASH lack definitive etiology, effective therapy, 
and evidence-based clinical guidelines. NAFLD/NASH is 
a diagnosis of exclusion, and none of the available noninva-
sive diagnostic methods/tests rule out other possible under-
lying diseases or stage the disease for prognostic purposes. 
Thus, liver biopsy will often be required to confirm the 
diagnosis, stage the disease, rule out other liver diseases, and 
determine the need and urgency of aggressive therapy.88
According to the World Gastroenterology Organization 
recommendations for NAFLD/NASH, it is likely that NASH 
will be found in patients who present with risk factors such 
as hypertension, type 2 diabetes, sleep apnea, a positive 
family history, nonblack ethnicity, obesity, hyperlipidemia, 
sedentary lifestyle, and/or ultrasound changes consistent 
with fatty liver. In approaching patients with persistent 
elevation of liver enzymes, it is necessary to exclude other 
liver diseases and use of potentially hepatotoxic medications 
that can cause fatty liver. If risk factors for NAFLD/NASH 
are present (ie, MS components), the patients should be first 
treated with diet and exercise. The World Gastroenterology 
Organization recommendation for NAFLD/NASH in 2014 
is a weight loss goal of 5%–10%, with a 25% decrease in 
calories from a normal diet. Moderate exercise three to four 
times per week is suggested as an exercise goal, as well as 
the proper control of diabetes, hyperlipidemia, and other 
cardiovascular risks. In the absence of improvement, and 
with rather abnormal ALT levels after 6 months’ follow-up, 
a liver biopsy should be considered.88
In the presence of potential signs of liver cirrhosis, AST . 
ALT, and low platelet and albumin levels in initial evaluation 
of patients with suspected NAFLD, liver biopsy should be 
considered. Patients with simple steatosis have good progno-
sis provided they receive treatment of the cardiovascular risk 
factors. If the diagnosis of NASH is confirmed, the treatment 
depends on patient’s BMI and associated risk factors. If the 
patient’s BMI is ,35 kg/m2, we advise first treatment with 
diet, exercise, and behavior modifications. If the patient’s 
BMI is .40 kg/m2 or .35 kg/m2 in the presence of associ-
ated risk factors, we advise treatment with diet, exercise, and 
behavior modifications, and also consideration of treatment 
with bariatric surgery. As it was mentioned, there is no 
evidence-based approved drug therapy for NAFLD/NASH 
to date. Thus, experimental therapy (including antioxidants 
and antifibrotic agents, such as vitamin E and pentoxifylline) 
should be considered by experienced clinicians in patients 
who fail to achieve 5%–10% weight reduction in 6 months 
to 1 year of successful lifestyle changes.88
Conclusion
While much progress has been made in elucidating the epi-
demiology, natural history, and pathogenesis of NAFLD, 
there remains no effective therapy for NAFLD patients in 
the general population. Several pharmacological agents 
have been studied in an effort to improve IR and the proin-
flammatory mediators that may be responsible for NASH 
progression. Additional investigations are warranted to 
establish the efficacy and safety of these medications. It is 
also important to treat the metabolic abnormalities that are 
often associated with NAFLD/NASH, such as hypertension, 
diabetes, dyslipidemia, and obesity. Statin therapy should be 
considered for patients with NAFLD/NASH and hypercho-
lesterolemia, while treatment with TZDs may be initiated 
for NAFLD/NASH patients with diabetes. RAAS blockers 
could be helpful for NAFLD/NASH patients with hyperten-
sion, especially if diabetes is also present. NASH patients 
show a high prevalence of cardiovascular risk factors, and 
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the backbone of treatment regimens for these patients still 
constitutes general lifestyle interventions, including dietary 
changes and increased physical activity.
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